A Phase 3 interventional study of Ivacaftor in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 20 sites in 3 countries. Open to participants aged 2 Years to 5 Years. Per ClinicalTrials.gov, last updated 2016-04-05.
Sponsored by Vertex Pharmaceuticals Incorporated · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 84 studies testing ivacaftor in Cystic Fibrosis — 4 open to participants now, 7 under way, 2 of them phase 3. ivacaftor · Cystic Fibrosis.
Among the 84 studies testing ivacaftor in Cystic Fibrosis, this one is the 61st largest by enrollment, is one of 8 that started in 2013, is one of 45 in phase 3, and was the 19th registered.
1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.
Browse Cystic Fibrosis studies →4 of the 84 studies testing ivacaftor in Cystic Fibrosis are open now, in 2 countries. Recruiting first, the newest first:
Istituto Giannina Gaslini · Sites in Italy
Ages 6+
Vertex Pharmaceuticals Incorporated · Sites in United States
Ages 18–55 · Healthy volunteers
Vertex Pharmaceuticals Incorporated · Sites in United States
Ages 18–55 · Healthy volunteers
Arkansas Children's Hospital Research Institute · Sites in United States
Ages 3+
By country, each count listing its studies:
ivacaftor: first FDA approval 2012 (KALYDECO), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.
This study: 2 Years to 5 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
84 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 18 · Phase 3 45 · Phase 4 7
First in 2007; this study’s year is marked. 8 started in 2013.
This study's enrollment of 35 is close to the median of 36 across 1,053 interventional studies indexed under Cystic Fibrosis.
Median enrollment 70 across the 84 interventional studies. Of the 76 that completed or were terminated, 64 (84%) have results posted.
This tab as a report to print or save as PDF → With an account.
74 of 84 have an industry lead sponsor. The 10 most frequent:
Vertex Pharmaceuticals Incorporated is the lead sponsor of 249 studies on the registry; 17 are open to participants now.
Of its 107 completed or terminated interventional studies of FDA-regulated products, 54 (50%) have results posted.
125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated: 3 open now, 8 under way, 5 of them phase 3. Of 112 finished, 80 (71%) have results posted.
Among the 125 studies in Cystic Fibrosis by Vertex Pharmaceuticals Incorporated, this one is the 87th largest by enrollment of the 116 interventional ones that give a count, is one of 11 that started in 2013, is one of 62 in phase 3, and was the 21st registered.
Vertex Pharmaceuticals Incorporated’s Cystic Fibrosis studies by the year they started, since 2007.
4 of the studies testing ivacaftor in Cystic Fibrosis that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05331183Phase 3Vertex Pharmaceuticals IncorporatedStudy to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del | 2027-04-06 |
| NCT06460506Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and Older | 2027-09-30 |
| NCT07437105Vertex Pharmaceuticals IncorporatedDose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants | 2027-06-26 |
| NCT07283770Vertex Pharmaceuticals IncorporatedEvaluation of VX-581 in Healthy Participants and in Participants With Cystic Fibrosis | 2027-07-12 |
Add all 4 to your calendar (.ics) → With an account.
Among the 84 studies testing ivacaftor in Cystic Fibrosis, from their registry updates:
Among Vertex Pharmaceuticals Incorporated’s 125 in Cystic Fibrosis:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD), of ivacaftor in children with cystic fibrosis (CF) who are 2 through 5 years of age and have a CF Transmembrane Conductance Regulator (CFTR) gating mutation in at least 1 allele.
Part A is designed to evaluate the safety and PK of multiple-dose administration of ivacaftor in participants 2 through 5 years of age and to confirm the doses for Part B. Part B is designed to evaluate the safety, PK, PD, and efficacy of ivacaftor in participants 2 through 5 years of age.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Part A: Ivacaftor 50 milligram (mg) (for participants weighing less than \[\<\] 14 kilograms \[kg\]) or 75 mg (for participants weighing greater than or equal to \[\>=\] 14 kg) every 12 hours (q12h) from Day 1 through Day 3 and 1 morning dose on Day 4 during Part A of the study.. Part B: Ivacaftor 50 mg (for participants weighing \<14 kg) or 75 mg (for participants weighing \>=14 kg) q12h for 24 weeks during Part B of the study.
Drug: Ivacaftor
Also known as: Kalydeco, VX-770
Part A: Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Related AEs
AE: any adverse change from participant's baseline (pre-treatment) condition, including any adverse experience, abnormal recording/clinical laboratory assessment which occurs during course of study, whether it is considered related to study drug or not. SAE: medical event or condition, which falls into any of following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, in-patient hospitalization/prolonged hospitalization, persistent/significant disability/incapacity, congenital anomaly/birth defect, important medical event. Related AEs includes all AEs for which the causality was either related to study drug or possibly related to study drug. Data was reported as per the dose received and for overall participants.
Time frame: Part A: Up to 93 Days
Part B: Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Related AEs
AE: any adverse change from participant's baseline (pre-treatment) condition, including any adverse experience, abnormal recording/clinical laboratory assessment which occurs during course of study, whether it is considered related to study drug or not. AE includes both serious and non-serious AE. SAE: medical event or condition, which falls into any of following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, in-patient hospitalization/prolonged hospitalization, persistent/significant disability/incapacity, congenital anomaly/birth defect, important medical event. Related AEs includes all AEs for which the causality was either related to study drug or possibly related to study drug. Data was reported as per the dose received.
Time frame: Part B: Up to 28 Weeks
Part A: Plasma Concentration of Ivacaftor and Its Metabolites
Plasma concentration was reported for ivacaftor and its metabolites (hydroxymethyl ivacaftor \[M1\] and ivacaftor carboxylate \[M6\]) up to 24 hours post-dose on Day 4 (Hour 0 \[pre-dose\] on Day 1 and Day 4; 2, 3, 6, 24 hours post-dose on Day 4). Data was planned to be reported for overall participants in the period.
Time frame: Part A: up to 24 hours post-dose on Day 4
Part B: Plasma Concentration of Ivacaftor and Its Metabolites
Plasma concentration was reported for ivacaftor and its metabolites (M1 and M6) up to 24 hours post-dose on Day 168 (Hour 0 \[predose\] on Day 1, 14, 56, 112, and 168; 2, 3, 6 hours post-dose on Day 14; 1 hour post-dose on Day 56; 4, 6 hours post-dose on Day 112; 24 hours post-dose on Day 168). Data was planned to be reported for overall participants in the period.
Time frame: Part B: up to 24 hours post-dose on Day 168
Part B: Absolute Change From Baseline in Sweat Chloride at Week 24
Sweat samples were collected using an approved Macroduct (Wescor, Logan, Utah) collection device. A volume of greater than or equal to (\>=) 15 microliter was required for determination of sweat chloride. Data was reported as per the dose received and for overall participants.
Time frame: Part B: Baseline, Week 24
Part B: Absolute Change From Baseline in Weight at Week 24
Data was reported as per the dose received and for overall participants.
Time frame: Part B: Baseline, Week 24
Part B: Absolute Change From Baseline in Stature at Week 24
Stature was measured as height if children could stand unassisted and follow directions; otherwise, stature was measured as length. Data was reported as per the dose received and for overall participants.
Time frame: Part B: Baseline, Week 24
Part B: Absolute Change From Baseline in Body Mass Index (BMI) at Week 24
BMI = (Weight \[in kg\]) divided by (Stature \[in meters\])\^2. Data was reported as per the dose received and for overall participants.
Time frame: Baseline, Week 24
| Milestone | Ivacaftor |
|---|---|
| Started | 9 |
| Completed | 9 |
| Not completed | 0 |
| Milestone | Ivacaftor |
|---|---|
| Started | 34 |
| Completed | 33 |
| Not completed | 1 |
| Withdrew: Adverse event | 1 |
AE: any adverse change from participant's baseline (pre-treatment) condition, including any adverse experience, abnormal recording/clinical laboratory assessment which occurs during course of study, whether it is considered related to study drug or not. SAE: medical event or condition, which falls into any of following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, in-patient hospitalization/prolonged hospitalization, persistent/significant disability/incapacity, congenital anomaly/birth defect, important medical event. Related AEs includes all AEs for which the causality was either related to study drug or possibly related to study drug. Data was reported as per the dose received and for overall participants.
| participants | Part A: Ivacaftor 50 mg | Part A: Ivacaftor 75 mg | Part A: Overall Ivacaftor |
|---|---|---|---|
| AEs | 3 | 5 | 8 |
| SAEs | 0 | 0 | 0 |
| Related AEs | 1 | 3 | 4 |
AE: any adverse change from participant's baseline (pre-treatment) condition, including any adverse experience, abnormal recording/clinical laboratory assessment which occurs during course of study, whether it is considered related to study drug or not. AE includes both serious and non-serious AE. SAE: medical event or condition, which falls into any of following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, in-patient hospitalization/prolonged hospitalization, persistent/significant disability/incapacity, congenital anomaly/birth defect, important medical event. Related AEs includes all AEs for which the causality was either related to study drug or possibly related to study drug. Data was reported as per the dose received.
| participants | Part B: Ivacaftor 50 mg | Part B: Ivacaftor 75 mg | Part B: Overall Ivacaftor |
|---|---|---|---|
| AEs | 10 | 23 | 33 |
| SAEs | 3 | 3 | 6 |
| Related AEs | 3 | 8 | 11 |
Plasma concentration was reported for ivacaftor and its metabolites (M1 and M6) up to 24 hours post-dose on Day 168 (Hour 0 \[predose\] on Day 1, 14, 56, 112, and 168; 2, 3, 6 hours post-dose on Day 14; 1 hour post-dose on Day 56; 4, 6 hours post-dose on Day 112; 24 hours post-dose on Day 168). Data was planned to be reported for overall participants in the period.
| ng/mL | Part B: Overall Ivacaftor |
|---|---|
| Ivacaftor: Hour 0 on Day 1 | 0.00 ± 0.00 |
| Ivacaftor: Hour 0 on Day 14 | 614 ± 590 |
| Ivacaftor: 2 Hours Post-Dose on Day 14 | 932 ± 541 |
| Ivacaftor: 3 Hours Post-Dose on Day 14 | 1080 ± 587 |
| Ivacaftor: 6 Hours Post-Dose on Day 14 | 1140 ± 627 |
| Ivacaftor: Hour 0 on Day 56 | 448 ± 455 |
| Ivacaftor: 1 Hour Post-Dose on Day 56 | 514 ± 421 |
| Ivacaftor: Hour 0 on Day 112 | 596 ± 747 |
| Ivacaftor: 4 Hours Post-Dose on Day 112 | 1080 ± 835 |
| Ivacaftor: 6 Hours Post-Dose on Day 112 | 1010 ± 885 |
| Ivacaftor: Hour 0 on Day 168 | 500 ± 545 |
| Ivacaftor: 24 Hours Post-Dose on Day 168 | 207 ± 372 |
| M1: Hour 0 on Day 1 | 0.00 ± 0.00 |
| M1: Hour 0 on Day 14 | 1580 ± 1030 |
| M1: 2 Hours Post-Dose on Day 14 | 1870 ± 924 |
| M1: 3 Hours Post-Dose on Day 14 | 2280 ± 1140 |
| M1: 6 Hours Post-Dose on Day 14 | 2670 ± 1080 |
| M1: Hour 0 on Day 56 | 1340 ± 880 |
| M1: 1 Hour Post-Dose on Day 56 | 1170 ± 698 |
| M1: Hour 0 on Day 112 | 1680 ± 1360 |
| M1: 4 Hours Post-Dose on Day 112 | 2450 ± 1510 |
| M1: 6 Hours Post-Dose on Day 112 | 2500 ± 1520 |
| M1: Hour 0 on Day 168 | 1460 ± 1200 |
| M1: 24 Hours Post-Dose on Day 168 | 602 ± 647 |
| M6: Hour 0 on Day 1 | 0.00 ± 0.00 |
| M6: Hour 0 on Day 14 | 1520 ± 1130 |
| M6: 2 Hours Post-Dose on Day 14 | 1430 ± 989 |
| M6: 3 Hours Post-Dose on Day 14 | 1630 ± 1130 |
| M6: 6 Hours Post-Dose on Day 14 | 2090 ± 1350 |
| M6: Hour 0 on Day 56 | 1510 ± 1080 |
| M6: 1 Hour Post-Dose on Day 56 | 1310 ± 974 |
| M6: Hour 0 on Day 112 | 1660 ± 1130 |
| M6: 4 Hours Post-Dose on Day 112 | 1810 ± 1230 |
| M6: 6 Hours Post-Dose on Day 112 | 2130 ± 1380 |
| M6: Hour 0 on Day 168 | 1520 ± 1130 |
| M6: 24 Hours Post-Dose on Day 168 | 632 ± 465 |
Sweat samples were collected using an approved Macroduct (Wescor, Logan, Utah) collection device. A volume of greater than or equal to (\>=) 15 microliter was required for determination of sweat chloride. Data was reported as per the dose received and for overall participants.
| millimole per liter (mmol/L) | Part B: Ivacaftor 50 mg | Part B: Ivacaftor 75 mg | Part B: Overall Ivacaftor |
|---|---|---|---|
| Part B: Absolute Change From Baseline in Sweat Chloride at Week 24 | -47.07 ± 24.256 | -46.78 ± 27.584 | -46.86 ± 26.193 |
Data was reported as per the dose received and for overall participants.
| kilograms (kg) | Part B: Ivacaftor 50 mg | Part B: Ivacaftor 75 mg | Part B: Overall Ivacaftor |
|---|---|---|---|
| Part B: Absolute Change From Baseline in Weight at Week 24 | 1.00 ± 0.418 | 1.50 ± 0.552 | 1.36 ± 0.561 |
Stature was measured as height if children could stand unassisted and follow directions; otherwise, stature was measured as length. Data was reported as per the dose received and for overall participants.
| centimeters (cm) | Part B: Ivacaftor 50 mg | Part B: Ivacaftor 75 mg | Part B: Overall Ivacaftor |
|---|---|---|---|
| Part B: Absolute Change From Baseline in Stature at Week 24 | 2.5 ± 1.45 | 3.5 ± 0.93 | 3.3 ± 1.17 |
Plasma concentration was reported for ivacaftor and its metabolites (hydroxymethyl ivacaftor \[M1\] and ivacaftor carboxylate \[M6\]) up to 24 hours post-dose on Day 4 (Hour 0 \[pre-dose\] on Day 1 and Day 4; 2, 3, 6, 24 hours post-dose on Day 4). Data was planned to be reported for overall participants in the period.
| nanogram per milliliter (ng/mL) | Part A: Overall Ivacaftor |
|---|---|
| Ivacaftor: Hour 0 on Day 1 | 0.00 ± 0.00 |
| Ivacaftor: Hour 0 on Day 4 | 396 ± 337 |
| Ivacaftor: 2 Hours Post-Dose on Day 4 | 726 ± 284 |
| Ivacaftor: 3 Hours Post-Dose on Day 4 | 957 ± 283 |
| Ivacaftor: 6 Hours Post-Dose on Day 4 | 542 ± 241 |
| Ivacaftor: 24 Hours Post-Dose on Day 4 | 124 ± 149 |
| M1: Hour 0 on Day 1 | 0.00 ± 0.00 |
| M1: Hour 0 on Day 4 | 1240 ± 723 |
| M1: 2 Hours Post-Dose on Day 4 | 1540 ± 578 |
| M1: 3 Hours Post-Dose on Day 4 | 2310 ± 820 |
| M1: 6 Hours Post-Dose on Day 4 | 1580 ± 622 |
| M1: 24 Hours Post-Dose on Day 4 | 389 ± 336 |
| M6: Hour 0 on Day 1 | 0.00 ± 0.00 |
| M6: Hour 0 on Day 4 | 1150 ± 709 |
| M6: 2 Hours Post-Dose on Day 4 | 1050 ± 606 |
| M6: 3 Hours Post-Dose on Day 4 | 1300 ± 614 |
| M6: 6 Hours Post-Dose on Day 4 | 1390 ± 532 |
| M6: 24 Hours Post-Dose on Day 4 | 439 ± 355 |
BMI = (Weight \[in kg\]) divided by (Stature \[in meters\])\^2. Data was reported as per the dose received and for overall participants.
| kilogram per square meter (kg/m^2) | Part B: Ivacaftor 50 mg | Part B: Ivacaftor 75 mg | Part B: Overall Ivacaftor |
|---|---|---|---|
| Part B: Absolute Change From Baseline in Body Mass Index (BMI) at Week 24 | 0.332 ± 0.5393 | 0.314 ± 0.5492 | 0.319 ± 0.5378 |
Collected over Part A: up to 93 days; Part B: up to 28 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A: Ivacaftor 50 mg | — | 0/4 (0%) | 3/4 (75%) |
| Part A: Ivacaftor 75 mg | — | 0/5 (0%) | 5/5 (100%) |
| Part A: Overall Ivacaftor | — | 0/9 (0%) | 8/9 (88.9%) |
| Part B: Ivacaftor 50 mg | — | 3/10 (30%) | 9/10 (90%) |
| Part B: Ivacaftor 75 mg | — | 3/24 (12.5%) | 23/24 (95.8%) |
| Part B: Overall Ivacaftor | — | 6/34 (17.6%) | 32/34 (94.1%) |
| Event | Part A: Ivacaftor 50 mg | Part A: Ivacaftor 75 mg | Part A: Overall Ivacaftor | Part B: Ivacaftor 50 mg | Part B: Ivacaftor 75 mg | Part B: Overall Ivacaftor |
|---|---|---|---|---|---|---|
| Infective pulmonary exacerbation of cystic fibrosisInfections and infestations | 0/4 | 0/5 | 0/9 | 1/10 | 1/24 | 2/34 |
| Device related sepsisInfections and infestations | 0/4 | 0/5 | 0/9 | 1/10 | 0/24 | 1/34 |
| Pseudomonas test positiveInvestigations | 0/4 | 0/5 | 0/9 | 1/10 | 0/24 | 1/34 |
| Transaminases increasedInvestigations | 0/4 | 0/5 | 0/9 | 1/10 | 0/24 | 1/34 |
| VomitingGastrointestinal disorders | 0/4 | 0/5 | 0/9 | 0/10 | 1/24 | 1/34 |
| ConvulsionNervous system disorders | 0/4 | 0/5 | 0/9 | 0/10 | 1/24 | 1/34 |
| Event | Part A: Ivacaftor 50 mg | Part A: Ivacaftor 75 mg | Part A: Overall Ivacaftor | Part B: Ivacaftor 50 mg | Part B: Ivacaftor 75 mg | Part B: Overall Ivacaftor |
|---|---|---|---|---|---|---|
| CoughRespiratory, thoracic and mediastinal disorders | 0/4 | 1/5 | 1/9 | 4/10 | 15/24 | 19/34 |
| PyrexiaGeneral disorders | 2/4 | 2/5 | 4/9 | 4/10 | 2/24 | 6/34 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 0/4 | 0/5 | 0/9 | 4/10 | 5/24 | 9/34 |
| RhinorrhoeaRespiratory, thoracic and mediastinal disorders | 0/4 | 2/5 | 2/9 | 2/10 | 5/24 | 7/34 |
| VomitingGastrointestinal disorders | 0/4 | 2/5 | 2/9 | 3/10 | 6/24 | 9/34 |
| EcchymosisSkin and subcutaneous tissue disorders | 0/4 | 2/5 | 2/9 | 0/10 | 0/24 | 0/34 |
| Upper respiratory tract infectionInfections and infestations | 0/4 | 0/5 | 0/9 | 1/10 | 7/24 | 8/34 |
| Rash macularSkin and subcutaneous tissue disorders | 1/4 | 0/5 | 1/9 | 0/10 | 0/24 | 0/34 |
| Upper respiratory track congestionRespiratory, thoracic and mediastinal disorders | 0/4 | 1/5 | 1/9 | 0/10 | 1/24 | 1/34 |
| Croup infectiousInfections and infestations | 0/4 | 0/5 | 0/9 | 2/10 | 1/24 | 3/34 |
Safety set included all participants who received at least 1 dose of study drug.
| Age, Continuous(years) | Ivacaftor |
|---|---|
| Part A (n = 9) | 3.1 ± 1.17 |
| Part B (n = 34) | 3.2 ± 0.96 |
| Sex/Gender, Customized(participants) | Ivacaftor |
|---|---|
| Part A (n = 9): Female | 3 |
| Part A (n = 9): Male | 6 |
| Part B (n = 34): Female | 6 |
| Part B (n = 34): Male | 28 |
The record gives a start of Jan 2013, a primary completion of Mar 2014 and a completion of Mar 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2015, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ivacaftor
Vertex Pharmaceuticals Incorporated →